DE60217698D1 - Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex - Google Patents

Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex

Info

Publication number
DE60217698D1
DE60217698D1 DE60217698T DE60217698T DE60217698D1 DE 60217698 D1 DE60217698 D1 DE 60217698D1 DE 60217698 T DE60217698 T DE 60217698T DE 60217698 T DE60217698 T DE 60217698T DE 60217698 D1 DE60217698 D1 DE 60217698D1
Authority
DE
Germany
Prior art keywords
treatment
antibody against
antigen complex
chronic radiation
ignition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217698T
Other languages
English (en)
Other versions
DE60217698T2 (de
Inventor
John Isaacs
Herman Waldmann
Geoffrey Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922741&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60217698(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of DE60217698D1 publication Critical patent/DE60217698D1/de
Application granted granted Critical
Publication of DE60217698T2 publication Critical patent/DE60217698T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60217698T 2001-09-26 2002-09-26 Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex Expired - Lifetime DE60217698T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123156 2001-09-26
GB0123156A GB2380127A (en) 2001-09-26 2001-09-26 Treatment of chronic joint inflammation
PCT/GB2002/004358 WO2003026692A2 (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex

Publications (2)

Publication Number Publication Date
DE60217698D1 true DE60217698D1 (de) 2007-03-08
DE60217698T2 DE60217698T2 (de) 2007-10-25

Family

ID=9922741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217698T Expired - Lifetime DE60217698T2 (de) 2001-09-26 2002-09-26 Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex

Country Status (10)

Country Link
US (1) US20050037004A1 (de)
EP (3) EP2199307B1 (de)
JP (1) JP4694784B2 (de)
AU (2) AU2002329423B2 (de)
CA (1) CA2461714C (de)
DE (1) DE60217698T2 (de)
ES (2) ES2389781T3 (de)
GB (1) GB2380127A (de)
PT (1) PT1432445E (de)
WO (1) WO2003026692A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6660948B2 (en) * 2001-02-28 2003-12-09 Vip Investments Ltd. Switch matrix
JP4473117B2 (ja) 2002-03-13 2010-06-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗αｖβ６抗体
EP1664116A4 (de) * 2003-08-22 2009-06-03 Biogen Idec Inc Verbesserte antikörper mit veränderter effektor-funktion und herstellungsverfahren dafür
PL1687066T3 (pl) * 2003-11-14 2013-01-31 Brigham & Womens Hospital Inc Sposoby modulowania odporności
UA103594C2 (ru) * 2004-04-06 2013-11-11 Новиммюн С.А. Способ лечения увеита
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
EP2399936A3 (de) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154-Antikörper
US7740856B2 (en) 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
SG10201504917PA (en) 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007117600A2 (en) * 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
SG10201504662WA (en) * 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2170951A2 (de) * 2007-05-31 2010-04-07 Genmab A/S Rekombinante nichtglykosylierte einwertige, gentechnologisch erhaltene halbantikörper
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993007899A1 (en) 1991-10-15 1993-04-29 The Wellcome Foundation Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
SE510197C2 (sv) 1997-02-06 1999-04-26 Asea Brown Boveri Förfarande och anordning för styrning av ett kondensatordon för en shuntkopplad statisk kompensatorenhet med deblockeringssignaler för indikering av icke strömförande tillstånd hos ingående ventiler
US5843597A (en) * 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance

Also Published As

Publication number Publication date
EP1432445B1 (de) 2007-01-17
WO2003026692A2 (en) 2003-04-03
EP1432445A2 (de) 2004-06-30
US20050037004A1 (en) 2005-02-17
JP2005506331A (ja) 2005-03-03
ES2389781T3 (es) 2012-10-31
AU2008207338A1 (en) 2008-09-04
JP4694784B2 (ja) 2011-06-08
CA2461714A1 (en) 2003-04-03
ES2279884T3 (es) 2007-09-01
PT1432445E (pt) 2007-03-30
EP2199307B1 (de) 2014-11-05
EP1803466A1 (de) 2007-07-04
EP1803466B1 (de) 2012-07-11
GB0123156D0 (en) 2001-11-21
DE60217698T2 (de) 2007-10-25
GB2380127A (en) 2003-04-02
AU2002329423B2 (en) 2008-05-15
EP2199307A1 (de) 2010-06-23
WO2003026692A3 (en) 2003-12-18
AU2008207338B2 (en) 2011-12-08
CA2461714C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
DE60217698D1 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
IL165193A (en) Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease
DE60141855D1 (de) Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
IT1318370B1 (it) Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
ATE471344T1 (de) Antikörper gegen vla-1
DE602004017614D1 (de) Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
NO20043996L (no) Fremgangsmate for frembringelse av API'er
ATE464068T1 (de) Antikörper gegen opgl
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
HK1096975A1 (en) Monoclonal antibody against influenza b virus and immunoassay instrument using the antibody
EP1575491A4 (de) Behandlung von nierenkarzinomen mit antikörpern gegen egfr
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATA9952002A (de) Verwendung eines antikörpers gerichtet gegen lewis-antigene
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP2270054A3 (de) Anti-Idiotyp-Antikörper des humanen monoklonalen Antikörpers SC-1 sowie ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
8363 Opposition against the patent